about
Enzymatic cyclization of a potent bowman-birk protease inhibitor, sunflower trypsin inhibitor-1, and solution structure of an acyclic precursor peptideOptimized orthogonal translation of unnatural amino acids enables spontaneous protein double-labelling and FRETMolecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein.Mimotopes of apical membrane antigen 1: Structures of phage-derived peptides recognized by the inhibitory monoclonal antibody 4G2dc1 and design of a more active analoguePrediction of structural stability of short beta-hairpin peptides by molecular dynamics and knowledge-based potentials.Phage display and molecular imaging: expanding fields of vision in living subjects.Optimization of a novel peptide ligand targeting human carbonic anhydrase IXSolid-phase peptide head-to-side chain cyclodimerization: discovery of C(2)-symmetric cyclic lactam hybrid α-melanocyte-stimulating hormone (MSH)/agouti-signaling protein (ASIP) analogues with potent activities at the human melanocortin receptorsTranslocation of Non-Canonical Polypeptides into Cells Using Protective AntigenUse of lantibiotic synthetases for the preparation of bioactive constrained peptidesDevelopment of peptides specifically modulating the activity of KLK2 and KLK3.Investigation of the substrate specificity of lacticin 481 synthetase by using nonproteinogenic amino acids.Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide.Effects of cyclic lipodepsipeptide structural modulation on stability, antibacterial activity, and human cell toxicity.A novel strategy for the solid-phase synthesis of cyclic lipodepsipeptidesSerum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs.NisT, the transporter of the lantibiotic nisin, can transport fully modified, dehydrated, and unmodified prenisin and fusions of the leader peptide with non-lantibiotic peptides.Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis.Structure-based derivation of peptide inhibitors to target TGF-β1 receptor for the suppression of hypertrophic scarring fibroblast activation.Model foldamers: applications and structures of stable macrocyclic peptides identified using in vitro selection
P2860
Q27640635-DE20C0B0-20CE-4895-AF59-FC9F480EB771Q30361640-84E9793B-0687-455B-8339-58BB2E026F13Q30911799-3AF24ABB-2871-4A8A-8790-CD539F271B9AQ33261308-6F977136-6F83-421E-A5BE-BA2A6ED4D672Q33338632-BF83C18F-28BF-44D7-A92D-F8D81AF1BD2BQ33849788-1D09B733-91F4-47F3-BF49-F28FE7A488C4Q34302457-4EB3E21F-660B-453E-B8DC-D3453041274AQ34583185-FF87ACA8-3193-408A-9A4F-282F08150A27Q35856399-5E07E149-6F60-47CC-B718-C0FE2E3B397FQ36755079-6B97881C-BEFA-4E9C-A40E-8753B765858BQ37216674-EC8878EA-EF7E-4265-AAAE-8B46417BE655Q37331578-BEE21855-0214-46BE-BA0C-E2D76C3A33F3Q37358334-B7CD0F63-8AC4-4451-8496-FF84AE26C64AQ41444760-B606FB71-E50B-4F7F-B1FC-0C171AA65C8AQ41860932-606963DA-CD11-4B61-BFA0-CBDB9E6ACFFFQ41979383-622CEE36-AB56-4480-A5CC-A484F8EBBDC3Q42623332-6A01F39C-CD50-45BD-BC54-53BA4136521EQ43087445-7442F2C3-544A-4061-B140-6E64C1F66F09Q48312508-5FB79FD7-C618-4C08-B8ED-1C639D2BCF0DQ57840920-E0171601-9C74-40E9-A41D-F20EFE51CAC0
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cyclization strategies in peptide derived drug design.
@ast
Cyclization strategies in peptide derived drug design.
@en
Cyclization strategies in peptide derived drug design.
@nl
type
label
Cyclization strategies in peptide derived drug design.
@ast
Cyclization strategies in peptide derived drug design.
@en
Cyclization strategies in peptide derived drug design.
@nl
prefLabel
Cyclization strategies in peptide derived drug design.
@ast
Cyclization strategies in peptide derived drug design.
@en
Cyclization strategies in peptide derived drug design.
@nl
P356
P1476
Cyclization strategies in peptide derived drug design.
@en
P2093
Peter P Roller
P304
P356
10.2174/1568026023394209
P577
2002-03-01T00:00:00Z